Anti-PD-L1 Rabbit Monoclonal Antibody (Clone:IHC411)
|Amount :||0.5 ml|
|Isotype :||Rabbit IgG|
|Purification :||Protein A/G Chromatography|
|Content :||Tris Buffer, pH 7.3 - 7.7, with 1% BSA and <0.1% Sodium Azide|
|Storage condition :||Store at 2°C - 8°C. Do not freeze.|
"Programmed Death-Ligand 1 (PD-L1), also known as CD274 or B7 Homolog 1 (B7-H1), is a transmembrane protein involved in suppressing the immune system and rendering tumor cells resistant to CD8+ T cell-mediated lysis through binding of the Programmed Death-1 (PD-1) receptor. Overexpression of PD-L1 may allow cancer cells to evade the actions of the host immune system. In renal cell carcinoma, upregulation of PD-L1 has been linked to increased tumor aggressiveness and risk of death, and, in ovarian cancer, higher expression of this protein has lead to significantly poorer prognosis. PD-L1 has also been linked to systemic lupus erythematosus and cutaneous melanoma. When considered in adjunct with CD8+ tumor-infiltrating lymphocyte density, expression levels of PD-L1 may be a useful predictor of multiple cancer types, including stage III non-small cell lung cancer, hormone receptor negative breast cancer, and sentinel lymph node melanoma."
Recommended dilutions: Immunohistochemical analysis: 1:100 - 1:200. However, this need to be optimized based on the research applications.
For Research Use Only. Not for use in diagnostic/therapeutics procedures.
|Subcellular location:||Endomembrane system|
|Post transnational modification:||Ubiquitinated; STUB1 likely mediates polyubiquitination of PD-L1/CD274 triggering its degradation.|
|Tissue Specificity:||Highly expressed in the heart, skeletal muscle, placenta and lung. Weakly expressed in the thymus, spleen, kidney and liver. Expressed on activated T- and B-cells, dendritic cells, keratinocytes and monocytes.|
|BioGrid:||118891. 48 interactions.|